Key facts
- Dualitas Therapeutics’s last known valuation is $87.0M (Sep 2025).
- It has raised $65.0M across 1 recorded rounds; the latest was Early Stage VC ($32.6M) in Jul 2025.
- Notable investors include Qiming Venture Partners, Alexandria Venture Investments, SV Health Investors, Versant Ventures, Chugai Venture Fund — 6 tracked in total.
- Dualitas Therapeutics has filed 1 Form D with the SEC, most recently Nov 2025 ($32.6M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Dualitas Therapeutics
Funding rounds
1 roundsAbout Dualitas Therapeutics
Developer of a bispecific antibody therapeutics platform designed for addressing immunology and inflammation. The company's platform integrates discovery and rapid candidate optimization to identify novel bispecific antibody candidates by functionally screening the entire cell surface, enabling patients with immune and inflammatory diseases to access therapies with the potential for greater pharmacologic activity and more meaningful clinical benefit.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2023
- Employees
- 15
- Website
- dualitastx.com/
- Ownership
- Privately Held (backing)
Dualitas Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dualitas Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dualitas Therapeutics in its N-PORT filings yet. We sweep new filings monthly.